BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15767818)

  • 21. Primary diffuse large B-cell lymphoma of the bladder.
    Hayashi A; Miyakawa Y; Bokuda K; Kimura T; Nakashima E; Irie R; Sugiura H; Suzuki T; Ohsone Y; Akizuki S
    Intern Med; 2009; 48(16):1403-6. PubMed ID: 19687587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 26. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma.
    Patarca R; Freidlander A; Harrington WJ; Cabral L; Byrnes JJ; Fletcher MA
    AIDS Res Hum Retroviruses; 1996 May; 12(8):645-9. PubMed ID: 8744574
    [No Abstract]   [Full Text] [Related]  

  • 29. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary gastric lymphoma in an HIV positive patient].
    Sebastián JJ; Fuentes J; García S; Uribarrena R; Yus C; Boldova I
    Rev Esp Enferm Dig; 1995 Oct; 87(10):731-4. PubMed ID: 8519540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
    Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
    Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
    [No Abstract]   [Full Text] [Related]  

  • 32. An unusual cause of pleural effusion.
    Youngster I; Vaisben E; Cohen H; Nassar F
    Age Ageing; 2006 Jan; 35(1):94-6. PubMed ID: 16364944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
    Mak YK; Chan CH; Li CK; Lee MP; Tsang YW
    Hong Kong Med J; 2003 Apr; 9(2):91-7. PubMed ID: 12668818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHOP plus rituximab--balancing facts and opinion.
    Cheson BD
    N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary mediastinal large B-cell lymphoma.
    Faris JE; LaCasce AS
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):125-33. PubMed ID: 19367254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care.
    Dada R
    Acta Haematol; 2017; 138(4):216-220. PubMed ID: 29212067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
    Lai S; Venugopal P; Leslie W
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):134-6. PubMed ID: 22402359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.